2179.HK Live signaler | Maksimer profitt med Getagraph.com

Live Chart Being Loaded With Signals

Commentary (26 apr 2024 @ 09:08):

Jiangsu Recbio Technology Co., Ltd., a vaccine company, engages in the research, development, and commercialization of subunit vaccines in the People's Republic of China...

Stats
Dagens volum	38 500.00
Gjennomsnittsvolum	11 048.00
Markedsverdi	4.37B
Neste inntjeningsdato	( HKD0 ) 2024-05-08
Last Dividend	HKD0 ( N/A )
Next Dividend	HKD0 ( N/A )
P/E	-7.08
ATR14	HKD0.0460 (0.50%)

Jiangsu Recbio Technology Korrelasjon

10 Mest positive korrelasjoner

10 Mest negative korrelasjoner

Visste du det?

Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).

Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.

Jiangsu Recbio Technology Økonomi

Annual	2023
Omsetning:	HKD30.38M
Bruttogevinst:	HKD22.34M (73.54 %)
EPS:	HKD-1.190

FY	2023
Omsetning:	HKD30.38M
Bruttogevinst:	HKD22.34M (73.54 %)
EPS:	HKD-1.190

FY	2022
Omsetning:	HKD5.33M
Bruttogevinst:	HKD5.33M (100.00 %)
EPS:	HKD-1.520

FY	2021
Omsetning:	HKD0.00
Bruttogevinst:	HKD0.00 (0.00 %)
EPS:	HKD-1.372

Financial Reports:

No articles found.

Jiangsu Recbio Technology

Jiangsu Recbio Technology Co., Ltd., a vaccine company, engages in the research, development, and commercialization of subunit vaccines in the People's Republic of China. The company is developing vaccines for the treatment of cervical cancer and genital warts, including REC603, a recombinant human papillomavirus (HPV) 9-valent vaccine that is in phase III clinical trial; REC601 and REC602 recombinant HPV bivalent vaccines, which are in phase I clinical trials; REC604a, a recombinant HPV quadrivalent vaccine that is in pre-clinical stage; and REC604b, a recombinant HPV 9-valent vaccine that is in pre-clinical stage. It is also developing ReCOV, a recombinant COVID-19 vaccine candidate that is in Phase II/III trial; and R520A, a messenger ribonucleic acid COVID-19 vaccine candidate that is in pre-clinical stage; REC610, a recombinant shingles vaccine that is in pre-clinical stage; REC607, a virus vectored adult tuberculosis vaccine that is in pre-clinical stage; REC606, a recombinant adult tuberculosis vaccine that is in pre-clinical stage; REC617, a recombinant influenza quadrivalent vaccine that is in pre-clinical stage; and REC605, a recombinant hand-foot-mouth disease quadrivalent vaccine that is in pre-clinical stage. The company was founded in 2011 and is based in Taizhou, the People's Republic of China.